Evidence map›Paper›PMID 42805778›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2026

Integrated computational and experimental identification of a novel ML-IAP-targeting peptide with antiproliferative activity in leukaemia cells.

Yan Wan, Yaozhi Hu, Ye Hong, Yanming Zhang, Na Hu, Jinrong Yao, Wenhui Fu, Xiaotian Yang, Junshuai Yue

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yan WanDepartment of Hematology, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China.
Yaozhi HuDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Ye HongDepartment of Clinical Nutrition/Department of Hematology, Binhai County People's Hospital, Yancheng, China.
Yanming ZhangDepartment of Hematology, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China.
Na HuDepartment of Hematology, Suqian No. 1 People's Hospital, Suqian, China.
Jinrong YaoDepartment of Hematology, Suqian No. 1 People's Hospital, Suqian, China.
Wenhui FuDepartment of Hematology, Suqian No. 1 People's Hospital, Suqian, China.
Xiaotian YangDepartment of Hematology, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China.
Junshuai YueDepartment of Hematology, Suqian No. 1 People's Hospital, Suqian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma inhibitor of apoptosis protein (ML-IAP) is an IAP family member involved in tumour cell survival and a potential target in ML-IAP-expressing leukaemia. Here, 59 319 tetrapeptides were screened against ML-IAP by molecular docking, and four top-ranked peptides were selected. Microscale thermophoresis confirmed binding of peptides 1-4 to ML-IAP, with peptide-1 showing the lowest

Indexed as

Antineoplastic AgentsInhibitor of Apoptosis ProteinsLeukemiaPeptidesCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsInhibitor of Apoptosis ProteinsPeptidesexperimental validationLeukaemiaML-IAPpeptidevirtual screening

Identifiers

PMID42805778
PMCPMC13629769

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.